{
  "schemaVersion" : 2,
  "registerId" : "F2018L00192",
  "instrumentNumber" : "19/2018",
  "citation" : "Statement of Principles concerning toxic retinopathy (Reasonable Hypothesis) (No. 19 of 2018)",
  "conditionName" : "toxic retinopathy",
  "effectiveFrom" : "2018-04-02",
  "standardOfProof" : "Reasonable Hypothesis",
  "icdCodes" : [ ],
  "onsetFactors" : [ {
    "paragraph" : "9(1)",
    "text" : "being treated with a quinoline-based drug as specified, before the\r\nclinical onset of toxic retinopathy",
    "definedTerms" : [ {
      "term" : "being treated with a quinoline-based drug as specified",
      "definition" : "means:\r\n(a) taking daily chloroquine for a continuous period of at least six months;\r\nor\r\n(b) taking a cumulative dose of chloroquine of at least 100 grams; or\r\n(c) taking daily hydroxychloroquine for a continuous period of at least five\r\nyears; or\r\n(d) taking a cumulative dose of hydroxychloroquine of at least 400 grams;\r\nor\r\n(e) taking daily quinacrine (mepacrine or Atebrin) for a continuous period\r\nof at least six months; or\r\n(f) taking a cumulative dose of quinacrine of at least 20 grams; or\r\n(g) taking a cumulative dose of at least 1000 mg of mefloquine within a\r\n30 day period."
    } ]
  }, {
    "paragraph" : "9(2)",
    "text" : "being treated with tamoxifen as specified within the one year before the\r\nclinical onset of toxic retinopathy",
    "definedTerms" : [ {
      "term" : "being treated with tamoxifen as specified",
      "definition" : "means:\r\n(a) taking daily tamoxifen for a continuous period of at least six months; or\r\n(b) taking a cumulative dose of tamoxifen of at least 100 grams."
    } ]
  }, {
    "paragraph" : "9(3)",
    "text" : "being treated with an intravitreal or subconjunctival aminoglycoside\r\nfrom the specified list of aminoglycosides, within the seven days\r\nbefore the clinical onset of toxic retinopathy",
    "definedTerms" : [ {
      "term" : "specified list of aminoglycosides",
      "definition" : "means:\r\n(a) amikacin;\r\n(b) gentamicin;\r\n(c) kanamycin;\r\n(d) netilmicin; or\r\n(e) tobramycin."
    } ]
  }, {
    "paragraph" : "9(4)",
    "text" : "being treated with intravitreal fomivirsen or ganciclovir within the 30\r\ndays before the clinical onset of toxic retinopathy",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(5)",
    "text" : "being treated with intravenous deferoxamine within the seven days\r\nbefore the clinical onset of toxic retinopathy",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(6)",
    "text" : "being treated with a phenothiazine from the specified list of\r\nphenothiazines for a continuous period of at least the two weeks before\r\nthe clinical onset of toxic retinopathy",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(7)",
    "text" : "being treated with daily clofazimine, at an average dose of at least\r\n100 milligrams per day, for a continuous period of at least the three\r\nmonths before the clinical onset of toxic retinopathy",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(8)",
    "text" : "being treated with ritonavir for a continuous period of at least the three\r\nmonths before the clinical onset of toxic retinopathy",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(9)",
    "text" : "being treated with interferon for a continuous period of at least four\r\nweeks, within the three months before the clinical onset of toxic\r\nretinopathy",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(10)",
    "text" : "being treated with daily topiramate for a continuous period of at least\r\nseven days within the 30 days before the clinical onset of toxic\r\nretinopathy",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(11)",
    "text" : "having iron chelating therapy as specified for a continuous period of at\r\nleast the four weeks before the clinical onset of toxic retinopathy",
    "definedTerms" : [ {
      "term" : "iron chelating therapy as specified",
      "definition" : "means:\r\n(a) daily oral deferasirox; or\r\n(b) daily oral deferiprone; or\r\n(c) subcutaneous or intramuscular deferoxamine."
    } ]
  }, {
    "paragraph" : "9(12)",
    "text" : "having haematological or biochemical evidence of poisoning with\r\ncobalt at the time of the clinical onset of toxic retinopathy",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(13)",
    "text" : "taking oral canthaxanthin supplements or tablets as specified within the\r\nfive years before the clinical onset of toxic retinopathy",
    "definedTerms" : [ {
      "term" : "taking oral canthaxanthin supplements or tablets as specified",
      "definition" : "means:\r\n(a) daily oral canthaxanthin supplements or tablets for a continuous period\r\nof at least six months; or\r\n(b) having a cumulative dose of at least 15 grams of canthaxanthin.\r\nNote: Canthaxanthin used as a colour additive in foods or drugs is excluded."
    } ]
  }, {
    "paragraph" : "9(14)",
    "text" : "inhaling isopropyl nitrite within the two weeks before the clinical onset\r\nof toxic retinopathy",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(15)",
    "text" : "using an intravenous drug containing talc within the five years before\r\nthe clinical onset of toxic retinopathy",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(16)",
    "text" : "for cystoid macular oedema only:\r\n(a) being treated with daily niacin for a continuous period of at least\r\ntwo weeks, at an average dose of at least 1.5 grams per day,\r\nwithin the three months before the clinical onset of toxic\r\nretinopathy;\r\n(b) being treated with intravenous paclitaxel or docetaxel within the\r\nthree months before the clinical onset of toxic retinopathy; or\r\n(c) being treated with the thiazolidinedione drugs rosiglitazone or\r\npioglitazone for a continuous period of at least the four weeks\r\nbefore the clinical onset of toxic retinopathy",
    "definedTerms" : [ {
      "term" : "cystoid macular oedema",
      "definition" : "means a painless disorder of the macula, in which\r\ndisruption of the normal blood-retinal barrier causes the accumulation of\r\nfluid within the intracellular spaces of the retina, primarily in the outer\r\nplexiform layer."
    } ],
    "conditionVariant" : {
      "name" : "cystoid macular oedema",
      "variantFactors" : [ {
        "paragraph" : "(a)",
        "text" : "being treated with daily niacin for a continuous period of at least\r\ntwo weeks, at an average dose of at least 1.5 grams per day,\r\nwithin the three months before the clinical onset of toxic\r\nretinopathy"
      }, {
        "paragraph" : "(b)",
        "text" : "being treated with intravenous paclitaxel or docetaxel within the\r\nthree months before the clinical onset of toxic retinopathy"
      }, {
        "paragraph" : "(c)",
        "text" : "being treated with the thiazolidinedione drugs rosiglitazone or\r\npioglitazone for a continuous period of at least the four weeks\r\nbefore the clinical onset of toxic retinopathy"
      } ]
    }
  }, {
    "paragraph" : "9(17)",
    "text" : "for cystoid macular oedema only, in an aphakic or pseudophakic eye\r\nonly:\r\n(a) being treated with topical adrenaline eye drops, within the three\r\nmonths before the clinical onset of toxic retinopathy; or\r\n(b) being treated with latanoprost within the three months before the\r\nclinical onset of toxic retinopathy",
    "definedTerms" : [ {
      "term" : "cystoid macular oedema",
      "definition" : "means a painless disorder of the macula, in which\r\ndisruption of the normal blood-retinal barrier causes the accumulation of\r\nfluid within the intracellular spaces of the retina, primarily in the outer\r\nplexiform layer."
    }, {
      "term" : "aphakic or pseudophakic eye",
      "definition" : "means an eye without a natural lens, or an eye\r\ncontaining an intraocular lens implant."
    } ],
    "conditionVariant" : {
      "name" : "cystoid macular oedema",
      "variantFactors" : [ {
        "paragraph" : "(a)",
        "text" : "being treated with topical adrenaline eye drops, within the three\r\nmonths before the clinical onset of toxic retinopathy"
      }, {
        "paragraph" : "(b)",
        "text" : "being treated with latanoprost within the three months before the\r\nclinical onset of toxic retinopathy"
      } ]
    }
  } ],
  "aggravationFactors" : [ {
    "paragraph" : "9(18)",
    "text" : "inability to obtain appropriate clinical management for toxic\r\nretinopathy",
    "definedTerms" : [ ]
  } ]
}